The poor prognosis for pancreatic ductal adenocarcinoma (PDAC) patients is due in part to
the highly fibrotic nature of the tumors that impedes delivery of therapeutics, including …

Simple Summary Our research team has identified the cholecystokinin-B receptor (or CCK-
BR) as a novel target for treatment of pancreatic cancer. CCK-BRs are over-expressed in …

Pancreatic stellate cells (PSCs) play a key role in desmoplastic stroma, which is a
characteristic of pancreatic ductal adenocarcinoma (PDAC), and they also enhance the …

Pancreatic ductal adenocarcinoma (PDAC) stands as a profoundly heterogeneous and
aggressive malignancy, manifesting a discouragingly limited response to conventional …

Pancreatic ductal adenocarcinoma (PDA) is characterized by abundant desmoplasia and
poor tissue perfusion. These features are proposed to limit the access of therapies to …

Pancreatic cancer is one of the most malignant tumors with one of the worst survival rates
due to its insidious onset and resistance to therapies. Most therapeutics show a desired …

The effectiveness of chemotherapy in PDAC is hampered by the dynamic interaction
between stroma and cancer cell. The two opposing schools of thought–non-depletion of the …

Simple Summary Pancreatic cancer is difficult to treat. Novel treatment strategies are
urgently needed to improve the survival rate, which is approximately 10% five years after …

Introduction and Objective Pancreatic cancer (PC) is characterized by a robust desmoplastic
environment, which limits the uptake of the standard first-line chemotherapeutic drug …

Simple Summary The tumor microenvironment of pancreatic cancer consists of dense
fibrotic stroma, which, to a certain extent, accounts for the relative drug resistance of this …